

Table 6*Hras* and *Ctnnb1* mutations in hepatocellular carcinomas in mice.

DE-71	Mutation frequency		<i>Hras</i> Cdn61 (CAA)			<i>Ctnnb1</i>
	<i>Hras</i> (%)	<i>Ctnnb1</i> (%)	AAA	CGA	CTA	Cdn 15-46
Control – Non-tumor liver	0/8 (0%)	0/8 (0%)	0	0	0	0
Control – Spontaneous hepatocellular tumors	2/17(12%)	0/17 (05) ^{##}	2	0	0	0
3 mg/kg	2/14 (14%)	3/14 (21%)	1	1	0	3
30 mg/kg	3/19 (16%)	1/19 (5%)	2	0	1	1
100 mg/kg	1/29 (3%)	9/29 (31%) ^{**}	1	0	0	9
All DE-71 treated groups (Combined)	6/62 (10%)	13/62 (21%)*	4	1	1	13

Male and female mice were dosed with 0, 3, 30, or 100 mg/kg PBDE mixture by oral gavage for 2 years. Silent mutations are not included. Non-tumor Liver – 0 mg/kg (3 males + 5 females); Liver Tumors- 0 mg/kg (14 males + 3 females); 3 mg/kg (12 males + 2 females); 30 mg/kg (13 males + 6 females); 100 mg/kg (15 males + 14 females).

Silent mutations not included.

* $p < 0.05$, ** $p < 0.01$ by Fisher's exact test to compare each dose group to the controls ^{##} $p < 0.01$ for trend by the Cochran–Armitage trend test.